In an Era of ctDNA, Is Metabolomics the New Kid on the Block?

Brian A Van Tine^{1

2

3}, Costas A Lyssiotis^{4

5

6}

Affiliations

¹ Department of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
² Department of Pediatric Hematology/Oncology, St. Louis Children's Hospital, St Louis, Missouri.
³ Siteman Cancer Center, St. Louis, Missouri.
⁴ Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan.
⁵ Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan.
⁶ Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.

PMID: 35140120
DOI: 10.1158/1078-0432.CCR-21-4180

Editorial

In an Era of ctDNA, Is Metabolomics the New Kid on the Block?

Brian A Van Tine et al. Clin Cancer Res. 2022.

. 2022 Apr 14;28(8):1477-1478.

doi: 10.1158/1078-0432.CCR-21-4180.

Authors

Brian A Van Tine^{1

2

3}, Costas A Lyssiotis^{4

5

6}

Affiliations

¹ Department of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
² Department of Pediatric Hematology/Oncology, St. Louis Children's Hospital, St Louis, Missouri.
³ Siteman Cancer Center, St. Louis, Missouri.
⁴ Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan.
⁵ Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan.
⁶ Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.

PMID: 35140120
DOI: 10.1158/1078-0432.CCR-21-4180

Abstract

Mass action drives the serum homeostasis of metabolites. Recent developments in biofluid metabolomics suggest the potential to harness these changes using small volumes of blood to diagnose, monitor, and risk stratify patients with cancer. This current study may represent a complementary technology to circulating tumor DNA detection. See related article by Larkin et al., p. 1651.

PubMed Disclaimer

Comment on

Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms.
Larkin JR, Anthony S, Johanssen VA, Yeo T, Sealey M, Yates AG, Smith CF, Claridge TDW, Nicholson BD, Moreland JA, Gleeson F, Sibson NR, Anthony DC, Probert F. Larkin JR, et al. Clin Cancer Res. 2022 Apr 14;28(8):1651-1661. doi: 10.1158/1078-0432.CCR-21-2855. Clin Cancer Res. 2022. PMID: 34983789 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

In an Era of ctDNA, Is Metabolomics the New Kid on the Block?

Affiliations

In an Era of ctDNA, Is Metabolomics the New Kid on the Block?

Authors

Affiliations

Abstract

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical